Qure.ai’s breathing tube placement AI technology receives FDA clearance

The algorithm improves critical care management for improper tube placements

New York, 20th Jan 2022: Leading health tech firm Qure.ai has gained 510(k) clearance from the Food and Drug Administration (FDA) for an artificial intelligence (AI) algorithm called qXR-BT, that will help doctors in assessing Breathing Tube (BT) placements. Through chest X-rays, the algorithm assists clinicians for intubated patients in locating the BT placement and automating measurements. This is the first solution of its kind to automate the manual measurement process for both endotracheal and tracheostomy tubes.

Verification of endotracheal tube (ETT) placement is imperative for the oxygenation, ventilation, and airway protection of your patient. While a common procedure done in hospitals daily, Rates for incorrect ET tube placement have been noted to be up to 25%. According to the Society of Airway Management, mistakes during the intubation process threaten the lives of 121,000 hospital intensive care unit patients annually in the United States. Even if you have an expert clinical team inserting and securing the tube after the initial placement, ETT migration is an inevitable consequence of coughing, suctioning, transport, and patient movement.

Qure's qXT-BT algorithm analyzes the tube position, automates measurement, and gives the physician a report on the tube’s positional accuracy in less than a minute. This enables clinicians to rapidly identify if the tube is properly positioned or whether extra attention is required. The algorithm is vendor-agnostic and is designed to work on both portable and stationary X-ray machines.

Dr. Mannudeep Kalra, attending thoracic radiologist, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School, who was involved in a research collaboration evaluating the technology said, “Daily monitoring of Tubes is critical for all intubated inpatients, and sometimes an arduous task on the portable exam with either the carina obscured or the tip not visible. An accurate AI solution could be a valuable aid for reporting on these chest X-rays- especially with the measurement.”

“We are pleased to have received FDA clearance for qXR-BT. In the last two years, we have seen the need to decrease processing times and solve workflow delays,” said Prashant Warier, CEO and Co-Founder, Qure.ai. “Especially in the wake of the COVID-19 pandemic and the need for mechanical ventilation in affected patients, the need for prompt assistance to an overburdened healthcare workforce is paramount,” he added.

qXR-BT is expected to become a standard feature of any critical care framework, giving residents and
junior clinicians more confidence in reliably measuring breathing tube placement in intubated patients.

Qure.ai bags second FDA clearance for Brain CT scan AI

qER-Quant will help enable faster diagnosis and help track patient progression over time

New York, 17th Aug 2021: Leading medical image AI provider Qure.ai has announced US FDA 510(k) clearance for its brain CT quantification product qER-Quant. Clinicians in the US can now use this tool to rapidly and precisely assess the severity of injury in patients with conditions like traumatic brain injury, hemorrhagic stroke, and hydrocephalus and to track the progression of pathology over time.

CT scans are the most widely used exam for brain injuries and are used to help diagnose millions of patients that visit the emergency room every year. AI assistance speeds up treatment and transfer decisions, helps monitor patients more closely and reduces the chances of diagnostic errors.

Ajith Thomas MD, Associate Professor of Neurosurgery, Harvard Medical School and Co-Director, Brain Aneurysm Institute, Beth Israel Deaconess Medical Center said, “The use of AI will be transformative in the management of traumatic brain injury by obtaining an expedient and accurate diagnosis. Congratulations to Qure.ai for being at the forefront of this paradigm shift!”

“Qure.ai’s technology makes it possible to systematically measure brain hemorrhages precisely and rapidly in patients with stroke or trauma. Fully automated quantification could soon become the standard of care.” says Dr Johan Wasselius, Interventional Neuroradiologist at the Skåne University Hospital and Lund University, Sweden.

“This FDA clearance adds quantification, outlining and measurement capabilities to Qure.ai’s first clearance for triage and notification of critical brain abnormalities. We are excited about bringing a complete suite of capabilities to clinicians who deal with critical head CT scans.” said Dr. Pooja Rao, Co-Founder and R&D head, Qure.ai.

“We’ve always built products to solve real customer challenges and qER Quant is another example of the same. We worked on this capability based on customer feedback from radiologists, neurologists, and ER physicians who expressed the need to get automated volume measurements on neuro scans to assess patient progress as well as safe discharge decisions. It helps us offer a more comprehensive suite of AI tools to our US clinical partners.” said Prashant Warier, CEO and co-founder, Qure.ai.

The FDA clearance and a summary of the performance of the software is available at this link. The AI tool is also cleared for marketing in the EU, and is currently used by teleradiology providers, emergency care physicians and radiologists at more than 40 clinical sites, helping process thousands of scans every day.

Qure.ai partners with Healthcare Imaging Services to bring Artificial Intelligence to chest X-ray diagnosis in Australia

16th July 2021, Sydney – Qure.ai leaders in developing deep learning algorithms for interpreting radiology images, is excited to announce a strategic partnership with Healthcare Imaging Services (HIS), the diagnostic imaging provider in the Healius Group.

The collaboration will see HIS integrating Qure’s artificial intelligence (AI) solutions to aid chest X-ray interpretation.

HIS has one of the largest networks of imaging centres in Australia and focuses on supplying high quality and comprehensive imaging diagnosis, annually processing close to three million scans. By using an automated X-ray screening technology called qXR from Qure, they will elevate patient care by aiding radiologists to prioritise critical cases, detect incidental findings and lower the chances of misdiagnosis.

The qXR AI algorithm can detect 30 distinct radiological abnormalities from chest X-rays, including lung opacities, nodules, cardiomegaly and pleural effusion. The first AI solution to be CE certified, qXR is now listed as a medical device on the Australian Register of Therapeutic Goods and has a sensitivity of over 95 per cent. Radiologists can use qXR as a pre-assistance read to separate normal from abnormal X-rays, making sure they get to the critical cases earlier.

Prashant Warier, CEO and co-founder of Qure.ai said, “Partnering with Healthcare Imaging Services is a significant milestone in making a positive contribution to Australia’s healthcare system. We are excited about how our AI technology for chest X-ray screening and interpretation can better the lives of both patients and medical personnel. Early disease detection has always been a critical factor in meticulous treatment, and better clinical outcomes for patients and our AI solution is geared to provide support to Australia’s doctors in both speed and accuracy of diagnoses.”

Dean Lewsam, CEO of Healthcare Imaging Services, is very excited about this collaboration: “This partnership is something as a business we are very excited about. We want to provide faster, more accurate care to our patients and the collaboration between our people across the country and qXR AI algorithm will allow us to do that.”

Qure.ai’s Brain CT AI wins funding from the NHS

The grant will help Qure.ai combine the power of artificial intelligence with the expertise of the NHS to improve patient outcomes

London, 16th June 2021 – Today, the UK Department of Health and Social Care announced that Qure.ai has been selected as one of the winners of the Artificial Intelligence in Health and Care Award, sponsored by the UK government. Qure.ai is a 5-year-old Sequoia-funded company builds Artificial Intelligence (AI) powered solutions to facilitate identification and treatment of stroke and head injuries. The Award has been instituted by the Accelerated Access Collaborative (AAC) in partnership with NHSX and the National Institute for Health Research (NIHR). The consortium is making £140 million available over four years in funding and support for promising AI technologies.

The award will drive Qure.ai’s mission to gather real-world evidence for its qER tool in an ER setting, in partnership with the NHS Guy’s and St. Thomas’ Foundation Trust, NHS King’s College Hospital Foundation Trust, NHS Northumbria Healthcare Foundation Trust and other key Major Trauma focused NHS trusts across the country.

qER is Qure.ai’s AI platform that identifies a range of critical abnormalities on head CT scans, such as bleeds, strokes and fractures. The technology is CE-marked and received United States FDA clearance in 2020. qER will now be deployed in Accident and Emergency (A&E) departments in the UK to improve diagnostic turn-around times for these critical conditions and help reduce missed diagnoses.

The NHS has seen a significant rise in A&E footfalls as well as growing volumes and complexity of imaging, with CT and MRI volumes increasing by an average of 10% (over half a million scans) per year, while patient wait times in the A&E have been steadily increasing too. For better patient outcomes, the time to diagnosis and treatment is critical, particularly for patients with neuro presentations such as head trauma or stroke.

Dr. Haris Shuaib, Consultant Physicist, Head of Clinical Scientific Computing at Guy’s and St Thomas’ NHS Foundation Trust said, “Our out-of-hours radiology reporting service would benefit greatly from an effective triaging and prioritisation system. With the qER system from Qure we hope to be able to manage critical findings like intracranial hemorrhage even more effectively.”

Dr Hugh Harvey, Managing Director, Hardian Health- “Winning a Phase 3 AAC award is a testimony to the strong consortium that has come together to support deployment and scaling of Qure’s market-leading qER software. Hardian Health is truly excited to be part of this fantastic consortium. We will be conducting cost-effectiveness analysis of the care pathways by involving all stakeholders, from NHS clinicians to patient advocacy groups”.

“We are excited about this Award from NHSX”, says Dr. Pooja Rao, R&D Head and co-founder of Qure.ai. “This NHSX grant will help us demonstrate that appropriate use of AI technology leads to better patient outcomes and accrues economic benefits to the NHS system. It paves the way for wider adoption of Qure’s technology in the UK”.

Qure.ai partners with the NGO PATH to accelerate and intensify COVID-19 screening

Qure’s AI technology now available on Telegram App for clinicians for instant chest X-ray interpretation

20th May 2021, Mumbai – India’s leading health-tech startup has collaborated with the international NGO PATH, to accelerate and intensify COVID-19 screening by making advanced AI diagnostic technology available to physicians across India through the Telegram App.

Qure’s CE-certified AI solution can read and interpret chest X-ray to detect findings indicative of COVID-19 as well as quantify the proportion of lungs affected due to the lesions. The technology which is being used by the Mumbai Municipal corporation and super-specialty hospitals across the globe, is now available to physicians on the Telegram app.

The second wave in India has led to a sharp scarcity of RT-PCR tests, as well as delayed reporting and lower accuracy in the test’s results. Qure’s AI solution can help as a preliminary screening mechanism. Chest X-rays are being increasingly preferred to assess and quantify the infection in the lungs as they are more easily available, inexpensive and inflict lower radiation levels. Qure’s AI bot would enable clinicians to triage for COVID-19 instantaneously. Physicians would only have to download the Qure bot from the Telegram app, upload the patient’s chest X-rays either as DICOMs images or as images taken by the smartphone camera. The result would be available in less than a minute and would serve as a second opinion or confirmation of diagnosis.

PATH is an international NGO which has been on the forefront of enabling digital transformation in India. Working with various state governments, they have a strong history of improving the effectiveness of health programs in 22+ states through their network of physicians and healthcare workers.

Prashant Warier, CEO and co-founder of Qure.ai said “What we’ve been seeing in the last few weeks is truly taking a toll on our frontline care givers and straining our public and private healthcare infrastructure severely. We need to implement and leverage technology that’s been extensively trained and validated to tackle this ongoing tragedy fast and it needs to be now.”

Dr. Shibu Vijayan, Global TB Technical Director, PATH said “Qure’s technology detects ground-glass opacities and consolidation, which are indicative of COVID-19 infections. It quantifies affected lung volume and gives a COVID-19 score which will help physicians decide on the course of treatment. It will also help healthcare institutions with optimizing their resource allocation.”

Fujifilm partners with Qure.ai to make intelligent X-ray solutions

Artificial Intelligence technology layer provides medics with diagnostic assistance by automaticallyinterpreting X-rays in a few seconds.

19th May, Mumbai: Fujifilm India Pvt. Ltd. is pleased to announce that FUJIFILM Corporation has introduced X-ray solutions augmented with qXR, Qure.ai’s computed aided radiology software application designed with deep-learning Artificial Intelligence (AI) technology. According to Qure.ai, the AI will analyze X-ray images to detect abnormal findings within seconds. Fujifilm’s portable X-ray FDR Xair system are equipped with a new image processing box called Expansion Unit EX-Mobile enabling to connect with qXR software. It will assist clinicians and technicians by flagging abnormal findings atthe point-of-care.

Qure’s peer-reviewed and proven chest X-ray interpretation technology, qXR can detect suspected abnormalities indicative of COVID-19, tuberculosis, lung cancer, misplaced catheters and multiple other radiological findings allowing for further review and confirmatory testing. The technology has been extensively trained on a global dataset and can be used for both adult as well as pediatric images.

Another significant advancement is that the combination of EX-Mobile with Fujifilm’s portable X-ray FDR Xair system
will bring the benefit of Qure’s AI technology not only to hospitals, but also regions which are geographically distant from the cities and emergency critical care. Furthermore, it will respond to the rapidly increasing global demand for support for effective lung procedures at medical sites, especially during the disease outbreaks.

“Fujifilm and Qure’s technology will deliver a support tool to assist the care providers for accurate diagnosis faster. With the help of Technology and special examination we can diagnose the disease while it is asymptomatic, with no signs or symptoms. The earlier detection of disease may lead to more cures or longer survival. Our partnership with Qure will support the expansion of Tuberculosis(TB) screening in India, and also other developing countries where there is limited access to such health service. We believe there’s tremendous potential in this partnership” said Koji Wada, General Manager, Fujifilm India Medical Division.”

“We are delighted to partner with Fujifilm to improve quality of care by accelerating patient triage, diagnostics and treatment. Qure.ai’s CE- certified and WHO endorsed technology will elevate patient care and reduce radiologists’ workload across healthcare institutions.” said Prashant Warier, CEO and Co-Founder, Qure.ai.

Fujifilm customers will be able to select one of the clinical packages available with qXR including:

  • qXR-COVID-19 which helps to monitor change of lung density.
  • qXR-Lung Nodule that enables early detection of metastatic lung cancer by automated pulmonary nodule detection.
  • qXR-TB helps reduce the waiting time for confirmatory tests for diseases like Tuberculosis.
  • qXR-Critical Care can detect misplaced catheters and tubes which are commonly used in critical care settings for monitoring body functions and administering medications.

Fujifilm and Qure aims provide high quality care in the increasingly dynamic and complex healthcare environment through future-proof AI technology.

1. Available in select CE Mark countries. Not available in all regions.

2. EX-Mobile is option product of Fujifilm’s FDR D-EVO II DR cassette.

AstraZeneca partners with Qure.ai to improve early stage diagnosis of lung cancer and reduce mortality rate in Latin America, Asia and Middle East & Africa regions

Partnership between AstraZeneca’s Emerging Markets Health Innovation Hubs and Qure.ai demonstrates ongoing commitment to integrate innovative new technologies into the healthcare ecosystem of developing markets

AstraZeneca has announced a partnership, through its Emerging Markets Health Innovation Hubs programme, with Qure.ai (developers of deep learning algorithms for the interpretation of radiology images) to integrate innovative artificial intelligence (AI) solutions for the early detection of lung cancer in patients across AstraZeneca’s Emerging Markets region, covering Latin America (Argentina, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic and other Caribbean Islands, Ecuador, Guatemala, Honduras, Peru, Panama, Mexico, Nicaragua and Uruguay), Asia (Philippines, Malaysia and Thailand in 2020 and India, Indonesia and Vietnam in 2021) and the Middle East & Africa (Gulf Cooperation Council countries).

Globally, chest X-rays are the most commonly ordered diagnostic imaging test, with millions of scans performed every year. Although chest X-rays are easily performed in primary care and referral settings, the interpretation of these X-rays requires significant skill and experience, and lack of expertise in reading the imaging can result in missed or delayed diagnosis.

A series of studies have described the use of deep learning algorithms to detect abnormalities, yielding promising results. ‘qXR’, Qure.ai’s chest X-ray interpretation tool, is able to automatically detect and localise up to 29 abnormalities, including those indicative of possible lung cancer. There are several features of chest radiographs (such as sharply circumscribed nodules or masses, those with irregular margins, and those with ill-defined lesions) that can indicate the presence of lung cancer. The CE-marked qXR algorithm can not only detect lung cancer nodules with high levels of accuracy in under a minute, but also marks out the position and size of these nodules. It can aid clinicians in picking up minuscule nodules which may be missed even by experts. A study conducted by Qure.ai demonstrated a 17% improvement in sensitivity when using AI to interpret chest X-rays, compared to radiologist readings. Such aids in early detection can have considerable long-term benefits for medical professionals in their efforts to tackle lung cancer. It can also mean lower cost per-life-year saved.

The AstraZeneca and Qure.ai partnership aims to harness and scale-up the use of this technology to improve early-stage detection of lung cancer in the markets involved, to reduce mortality rates and improve patient outcomes. As part of the strategic collaboration, AstraZeneca’s Emerging Markets Health Innovation Hubs will work with Qure.ai to explore the application of deep learning algorithms to identify patients with suspicious radiographic lung abnormalities and support their referral to arrive at a firm diagnosis. The collaboration will also focus on overcoming barriers that limit access to diagnostic tools to support early lung cancer detection.

The end goal of the partnership is to improve referral and diagnostic pathways for patients with possible lung cancers and increase lung cancer detection at an earlier stage – improving the patient journey and ultimately reducing lung cancer mortality rates around the world.

Leon Wang, AstraZeneca EVP International and Country President China, said “Improving long-term outcomes in lung cancer relies heavily on clinicians being able to identify patients in the early stages of the disease – giving them a better chance to provide curative-intent treatment. Qure.ai’s deep learning algorithm-based technology has the potential to provide clinicians with faster, more accurate diagnoses based on chest X-rays, helping secure those early-stage diagnoses and deliver better outcomes for patients. Innovations such as this are critical for boosting the capabilities of healthcare ecosystem, not just in Emerging Markets, but around the world, and this partnership supports our bold ambition of eliminating cancer as a cause of death.”

Prashant Warier, CEO and Co-Founder, Qure.ai, said “We are delighted to partner with AstraZeneca in the early detection of lung cancer using our AI solution for automated interpretation of chest X-rays. The software’s ability to process analogue and digital chest X-rays in a minute can help physicians in incidental diagnoses of lung cancer by pointing out small lung nodules which could have been missed in a cursory review. The solution also detects several other types of abnormalities from chest X-rays that are linked to infection, injuries and chronic diseases, and flags these to the physician, potentially creating other diagnostic pathways.”

Qure.ai’s tech is as reliable as radiologists for COVID assessment

A clinical study successfully evaluated Qure.ai algorithm’s ability to predict adverse clinical outcomes in patients with COVID-19

Health tech firm Qure.ai’s diagnostic tool for COVID-19 has been used as part of a clinical study conducted in Milan by IRCCS Ospedale San Raffaele. The study focused on the early predictors of clinical outcomes of COVID-19 and showed that the performance of Qure.ai’s chest X-ray interpretation technology, qXR, was comparable to radiologists’ assessment in predicting severity in initial chest x-rays in patients with COVID-19.

Published in European Radiology, the article stated that a high qXR chest X-ray quantitative score, based on percent of lung involvement, at admission was highly predictive of mortality due to COVID-19. This was comparable to what was obtained with the RALE score, previously validated to evaluate Acute Respiratory Distress Syndrome (ARDS).

IRCCS Ospedale San Raffaele has been using qXR technology since early April to aid the efforts of their physicians in pandemic management. qXR is one of Qure.ai’s AI-driven and machine-powered healthcare tools. It automatically generates chest X-ray interpretation reports and is faster and more efficient than humans in detecting, tuberculosis, chronic obstructive pulmonary diseases, lung malignancies and medical emergencies and in evaluating COVID-19 X-rays.

“As reported in our study, a qXR score ≥ 30 on chest x-rays at presentation is an independent predictor of of admission to intensive care unit (ICU) or deaths occurring before ICU admission in COVID-19 patients. These important findings of our study suggest that chest Xray and Artificial Intelligence may play a pivotal role in prognostic evaluation of COVID-19 disease” stated Professor Francesco De Cobelli, Head of Clinical and Experimental Radiology at IRCCS Ospedale San Raffaele.

Prashant Warier, CEO and co-founder of Qure.ai, said: “Our AI solution for chest X-rays qXR has proven to be useful in two areas in pandemic management. Firstly, to screen for individuals exhibiting signs of COVID-19 on a chest X-ray. Secondly, to monitor confirmed cases of COVID-19 to track the progression of the disease. Having deployed both these capabilities in hospitals and community screening programs across the globe, this study with Ospedale San Raffaele backs qXR’s ability to be an effective tool for predicting clinical outcomes at the first patient evaluation itself.”

Health-tech firm Qure.ai announces the appointment of Terri Bresenham to its board of advisors

Qure.ai today announced the appointment of Terri Bresenham to their advisory team. Terri will provide counsel and serve as a commercial advisor for Qure’s global market expansion. She brings with her 30 years of experience in the healthcare field and most recently served as the Chief Innovation Officer at GE Healthcare, leading transformation and growth.

“We’re delighted to have Terri on our team. She has led global businesses with exceptional success. Her experience in building new market models for sustainable healthcare will greatly benefit Qure as we expand our global operations,” said Prashant Warier, CEO and founder, Qure.ai.

“I am thrilled to join Qure’s advisory board, as we mutually share the passion of improving healthcare standards across the world. They are at an exciting time in their growth and I look forward to supporting their market expansion and positive impact to patient care.” commented Terri Bresenham.

Bresenham has led product development for medical devices, digital platforms and most recently clinical data science working with some of the most respected health systems across the world. She is a board member for several healthcare organizations, is active in community-based health projects, and is a champion for women leadership in technology and global health.

Nordic MedTech joins forces with Qure.ai to provide radiology practices with superior Artificial Intelligence technology

Nordic MedTech today announced that they have joined forces with Qure.ai to deploy advanced artificial intelligence (AI) technology for medical imaging diagnostics in the Nordics and Baltic regions.

The new distribution agreement will see Qure.ai’s head CT scan interpretation and triage aid “qER”, and chest x-ray interpretation tool “qXR” available to practices in Sweden, Denmark, Norway, Finland, Iceland, Estonia, Latvia, Lithuania and associated geographies. Both solutions are CE Certified and are aimed to improve clinician productivity and patient outcomes in diagnostic imaging.

Qure’s emergency room head CT tool, qER, is the only US FDA cleared solution that can be used to triage for intracranial bleeds, mass effect, midline shift, and cranial fractures. It helps prioritize radiology worklists and notifies when head CT scans with critical abnormalities are detected. It can also be used as a traumatic brain injury (TBI) progress monitoring tool and is offered with a reporting assistance mode that pre-populates radiologist templates.

Qure.ai’s qXR solution will analyse chest X-rays to deliver faster and more accurate detection of 24 of the most common lung abnormalities including opacities, tracheal shift, cardiomegaly, and pleural effusion with high levels of accuracy. The software generates a description of the findings, including name, size, and location of the abnormality, reducing the chances of potentially life-threatening missed diagnoses. The solution can also be used to triage and quantify COVID-19 infection in the lungs of patients.

“We are excited to partner with the capable team at Nordic MedTech and look forward to jointly take our solutions to radiologists and clinicians in the Nordic markets. Our commitment to our partners ans customers is to give them quality solutions that improve the accuracy of diagnoses and streamline clinical workflows and eventually enable better patient health outcomes”, said Prashant Warier, CEO and Co-founder, Qure.ai.

“By joining forces with Qure.ai we have taken a big leap forward to help our customers in their clinical daily routine. With solutions that is applicable both in the emergency rooms as well for chest X-rays we are convinced this is an important piece in the radiology puzzle and in the end for the best possible patient outcome”, said Pierre Vestman, CEO and Co-founder, Nordic MedTech AB.